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Received June 29, 2011; accepted October 12, 2011AbstractTreatment for non-small-cell lung cancer with gefitinib and erlotinib is efficacious. However, while many studies have reported on gefitinib-
related interstitial lung disease (ILD), less published data are available regarding erlotinib-induced ILD. Here, we report a case of pulmonary
adenocarcinoma who developed ILD due to gefitinib initially and erlotinib thereafter. The two episodes of ILD were treated successfully with the
discontinuation of the tyrosine kinase inhibitors and high-dose intravenous corticosteroids.
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Interstitial lung disease (ILD) is an infrequent but severe
adverse effect of gefitinib treatment.1e3 For patients dis-
continuing gefitinib due to ILD the safety of a subsequent
therapy with another small molecular epidermal growth factor
receptor-tyrosine kinase inhibitor (EGFR-TKI), erlotinib,
remained uncertain.
2. Case report
A 44-year-old man was diagnosed with lung adenocarci-
noma with right pleural seeding. He received cisplatin and
docetaxel every 3 weeks as an initial anticancer treatment.
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http://dx.doi.org/10.1016/j.jcma.2013.01.012tomography (CT) revealed a new onset of right loculated
pleural effusion (Fig. 1), and disease progression was docu-
mented. Gefitinib (250 mg/d) was administered as a second-
line treatment. However, the patient suffered from exertional
dyspnea 3 weeks after the administration of gefitinib. A plain
chest radiograph (Fig. 2) revealed right loculated pleural
effusion and extensive interstitial infiltration in the left lung.
High-resolution CT (Fig. 3) showed ground-glass opacities in
both lungs. Gefitinib-induced interstitial pneumonitis was
impressed. Immediate withdrawal of gefitinib and adminis-
tration of methylprednisolone 2 mg/kg/d was prescribed. The
patient’s dyspnea improved 6 days later. A follow-up plain
chest radiograph revealed improvement in ILD (Fig. 4). Sub-
sequent treatment with other cytotoxic chemotherapies was
suggested, but the patient requested treatment with another
EGFR-TKI, erlotinib. The patient was carefully informed of
high-fatality complications of erlotinib before its administra-
tion. After informed consent was received, erlotinib (75 mg/d)
combined with steroids was introduced 10 days later. Two
weeks later, dyspnea with hypoxemia occurred again, and
another chest CT (Fig. 5) showed the recurrence of ILD.hinese Medical Association. All rights reserved.
Fig. 3. Chest computed tomography showed diffuse interstitial infiltrates over
left lung (thin arrows) and right loculated pleural effusion (thick arrows) on the
3rd week of gefitinib therapy.
Fig. 1. Chest computed tomography before gefitinib administration revealed
right loculated malignant pleural effusion and no pre-existing interstitial lung
disease.
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steroid (methylprednidolone 2 mg/kg/d) was readministered.
The patient’s condition improved after treatment, and he was
discharged 1 week later.3. Discussion
Gefitinib and erlotinib are both small-molecule EGFR-
TKIs, and they are both second- and third-line treatments for
advanced or metastatic non-small-cell lung cancer in Asia.
There is the potential risk of drug-induced ILD by using these
two target therapy agents, especially gefitinib.1e3 The world-
wide reported incidence of ILD following gefitinib adminis-
tration is estimated at 1% (approximately 2% in Japan andFig. 2. Chest X-ray showed diffuse ground-glass zones in the left lung (thin
arrows) and right loculated pleural effusion (thick arrow) on the 3rd week of
gefitinib therapy.0.3% in the United States).4 However, few case reports have
revealed successful treatment with erlotinib after gefitinib-
induced interstitial pneumonitis.5,6 Another case report
showed that one patient who previously tolerated gefitinib
developed ILD after receiving erlotinib treatment.7 The risk
factors for gefitinib-induced ILD include a smoking history,
male gender, and the coincidence of interstitial pneumonia.8
One study compared the two TKIs for the incidence of ILD,
and the results showed that poor performance status and prior
pulmonary fibrosis were significantly correlated with the
occurrence of ILD, but not with the type of TKI.9 The etiologyFig. 4. A follow-up chest X-ray revealed improvement with regard to inter-
stitial lung disease (thin arrows) and right loculated pleural effusion (thick
arrows) 6 days after discontinuation of gefitinib and steroid treatment.
Fig. 5. Chest computed tomography performed 2 weeks after erlotinib
rechallenge showed recurrence of interstitial lung disease (thin arrows) and
right loculated pleural effusion (thick arrows).
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understood. One study suggested that gefitinib therapy may
augment any underlying pulmonary fibrosis via a decrease in
EGFR phosphorylation, based on a coincident decrease in
regenerative epithelial proliferation in a murine model.10
Successful treatment of gefitinib-induced ILD with high-
dose intravenous corticosteroids has been reported in many
cases,11,12 but only one report reveals that intravenous corti-
costeroids may be beneficial in cases of erlotinib-induced
ILD.13 Therefore, carefully evaluating a patient’s new onset
of respiratory symptoms (e.g., dyspnea, dry cough) after TKI
administration is very important and early discontinuation of
such agents is beneficial to patients. The role of corticosteroids
for TKI-induced ILD may need more trials to support the
notion of perceived benefits. In our report, both gefitinib and
erlotinib have the potential of inducing ILD in one patient.
This case reminds us that substitution with another EGFR-TKI
still has the risk of developing a similar pulmonary toxicity.References
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